Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a Healthcare company (Biotechnology) with a market capitalization of $103M. The Maz Rating grades it against the other companies in its sector.
Unicycive Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.70, Unicycive Therapeutics, Inc. trades at 2.0x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -83.3%, return on invested capital of -65.2% and a free cash flow yield of -28.5%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 4.00. Over the past 52 weeks the share price ranged from $3.33 to $8.74, with a beta of 1.86.
Unicycive Therapeutics, Inc. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 8 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Unicycive Therapeutics, Inc. (UNCY) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 49.3% / 30% · Interest income / Revenue 50300000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 49.3% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 50300000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 49.3% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 50300000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.17% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 84.6% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 50300000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 84.3% / 33.33% · (Cash+Recv) / Total Assets 84.3% / 33.33% · Interest income / Revenue 50300000.0% / 5% | Fail |
No. As of September 2026, Unicycive Therapeutics, Inc. (UNCY) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Unicycive Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 50300000.0% of each dividend: Unicycive Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.